Envestnet Asset Management Inc. Decreases Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Envestnet Asset Management Inc. trimmed its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 11.4% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 103,422 shares of the biopharmaceutical company’s stock after selling 13,305 shares during the quarter. Envestnet Asset Management Inc. owned 0.10% of Regeneron Pharmaceuticals worth $54,292,000 at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of REGN. Brighton Jones LLC grew its position in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company’s stock worth $675,000 after buying an additional 686 shares in the last quarter. Vontobel Holding Ltd. lifted its stake in Regeneron Pharmaceuticals by 13.6% in the first quarter. Vontobel Holding Ltd. now owns 7,339 shares of the biopharmaceutical company’s stock worth $4,655,000 after acquiring an additional 881 shares during the last quarter. DAVENPORT & Co LLC acquired a new position in Regeneron Pharmaceuticals during the 1st quarter worth approximately $271,000. Rossby Financial LCC purchased a new stake in shares of Regeneron Pharmaceuticals in the 1st quarter valued at approximately $87,000. Finally, Keybank National Association OH raised its holdings in shares of Regeneron Pharmaceuticals by 23.7% in the 1st quarter. Keybank National Association OH now owns 1,533 shares of the biopharmaceutical company’s stock valued at $972,000 after purchasing an additional 294 shares in the last quarter. Institutional investors and hedge funds own 83.31% of the company’s stock.

Insider Buying and Selling

In other news, Director Christine A. Poon sold 6,500 shares of the company’s stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the sale, the director directly owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Corporate insiders own 7.02% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages recently commented on REGN. BMO Capital Markets boosted their target price on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the stock an “outperform” rating in a research note on Monday, August 4th. Sanford C. Bernstein lifted their price target on Regeneron Pharmaceuticals from $753.00 to $781.00 and gave the stock an “outperform” rating in a report on Wednesday, August 27th. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Regeneron Pharmaceuticals in a research report on Wednesday, October 8th. Cantor Fitzgerald raised their target price on Regeneron Pharmaceuticals from $678.00 to $740.00 and gave the stock an “overweight” rating in a research report on Wednesday. Finally, Truist Financial decreased their target price on Regeneron Pharmaceuticals from $940.00 to $812.00 and set a “buy” rating for the company in a research note on Monday, August 11th. Three research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating, seven have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $802.36.

Regeneron Pharmaceuticals Price Performance

Shares of NASDAQ REGN opened at $651.80 on Friday. The stock has a market cap of $69.08 billion, a P/E ratio of 15.61, a P/E/G ratio of 2.03 and a beta of 0.31. Regeneron Pharmaceuticals, Inc. has a twelve month low of $476.49 and a twelve month high of $883.15. The stock has a 50 day moving average of $581.80 and a two-hundred day moving average of $565.22. The company has a current ratio of 4.06, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The business had revenue of $3.75 billion for the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The company’s revenue for the quarter was up .9% compared to the same quarter last year. During the same period last year, the firm posted $12.46 earnings per share. On average, research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, December 5th. Shareholders of record on Thursday, November 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, November 20th. This represents a $3.52 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s payout ratio is currently 8.43%.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.